Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:AYTU NASDAQ:LMNL NASDAQ:LPTX NASDAQ:OTIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.98+40.4%$2.21$1.32▼$381.10$4.64M5.776.54 million shs114.52 million shsAYTUAytu BioPharma$2.37+2.2%$2.35$0.95▼$2.85$20.83M0.2297,727 shs84,442 shsLMNLLiminal BioSciences$8.50$8.47$3.10▼$8.50$26.35M1.0363,470 shsN/ALPTXLeap Therapeutics$0.32+2.7%$0.31$0.22▼$4.79$12.97M-0.21665,769 shs724,823 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+40.43%+32.00%-0.50%-52.52%-99.96%AYTUAytu BioPharma+2.16%+3.04%+7.73%+18.50%-4.05%LMNLLiminal BioSciences0.00%0.00%0.00%0.00%0.00%LPTXLeap Therapeutics+2.72%+12.73%+12.22%-15.42%-88.84%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.98+40.4%$2.21$1.32▼$381.10$4.64M5.776.54 million shs114.52 million shsAYTUAytu BioPharma$2.37+2.2%$2.35$0.95▼$2.85$20.83M0.2297,727 shs84,442 shsLMNLLiminal BioSciences$8.50$8.47$3.10▼$8.50$26.35M1.0363,470 shsN/ALPTXLeap Therapeutics$0.32+2.7%$0.31$0.22▼$4.79$12.97M-0.21665,769 shs724,823 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+40.43%+32.00%-0.50%-52.52%-99.96%AYTUAytu BioPharma+2.16%+3.04%+7.73%+18.50%-4.05%LMNLLiminal BioSciences0.00%0.00%0.00%0.00%0.00%LPTXLeap Therapeutics+2.72%+12.73%+12.22%-15.42%-88.84%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.50Strong Buy$219,040.0011,062,526.26% UpsideAYTUAytu BioPharma 3.00Buy$10.00321.94% UpsideLMNLLiminal BioSciences 0.00N/AN/AN/ALPTXLeap Therapeutics 2.00Hold$3.38950.09% UpsideOTICOtonomy 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OTIC, AYTU, LMNL, APVO, and LPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025APVOAptevo TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$65.21 per shareN/AAYTUAytu BioPharma$81M0.26N/AN/A$4.64 per share0.51LMNLLiminal BioSciences$310K85.00N/AN/A$8.97 per share0.95LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)AYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/23/2025 (Estimated)LMNLLiminal BioSciences$380K$0.2929.31∞N/A248.35%-88.44%-64.15%N/ALPTXLeap Therapeutics-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ALatest OTIC, AYTU, LMNL, APVO, and LPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/23/2025Q4 2025AYTUAytu BioPharma-$0.02N/AN/AN/AN/AN/A8/14/2025Q2 2025LPTXLeap Therapeutics-$0.29-$0.40-$0.11-$0.40N/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27AYTUAytu BioPharma0.271.030.87LMNLLiminal BioSciences0.022.782.78LPTXLeap TherapeuticsN/A1.341.34OTICOtonomyN/A1.741.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%AYTUAytu BioPharma33.49%LMNLLiminal BioSciences0.66%LPTXLeap Therapeutics30.46%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%AYTUAytu BioPharma3.60%LMNLLiminal BioSciences2.20%LPTXLeap Therapeutics7.50%OTICOtonomy1.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.29 millionNot OptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableLMNLLiminal BioSciences2513.10 million3.04 millionNot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableOTICOtonomy5168.53 million67.78 millionOptionableOTIC, AYTU, LMNL, APVO, and LPTX HeadlinesRecent News About These CompaniesOtonomy's hearing loss drug shows no benefit in trial, tanking sharesSeptember 3, 2024 | pharmaphorum.comPTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023April 21, 2024 | straight.comSAllergic Contact Dermatitis and Topical AntibioticsSeptember 10, 2023 | medscape.comMHearing Loss in AdultsAugust 21, 2023 | nejm.orgNResearch PublicationsAugust 4, 2023 | slu.eduSManagement of Pediatric Otitis MediaMay 11, 2023 | medscape.comMHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRMay 8, 2023 | news.google.comNAlluvial Capital Management Q1 2023 Letter To Partners - Seeking AlphaApril 28, 2023 | news.google.comNVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital JournalApril 27, 2023 | news.google.comNHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRApril 25, 2023 | news.google.comNENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital JournalApril 24, 2023 | news.google.comNHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital JournalApril 11, 2023 | news.google.comNENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital JournalApril 10, 2023 | news.google.comN[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital JournalApril 10, 2023 | news.google.comNHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital JournalApril 3, 2023 | news.google.comNHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints NewsMarch 30, 2023 | news.google.comNAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints NewsMarch 30, 2023 | news.google.comNMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints NewsMarch 30, 2023 | news.google.comNBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints NewsMarch 30, 2023 | news.google.comNSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints NewsMarch 30, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025The Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025AEHR Spikes 36% on Hyperscaler Order—Investors Should Take NoticeBy Leo Miller | August 27, 2025OTIC, AYTU, LMNL, APVO, and LPTX Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.98 +0.57 (+40.43%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.83 -0.15 (-7.58%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Aytu BioPharma NASDAQ:AYTU$2.37 +0.05 (+2.16%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$2.40 +0.02 (+1.05%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Liminal BioSciences NASDAQ:LMNLLiminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Leap Therapeutics NASDAQ:LPTX$0.32 +0.01 (+2.72%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$0.31 -0.01 (-3.55%) As of 09/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
